Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Vineet Ahuja, Ida Hilmi, Byong Duk Ye, Khoon Lin Ling, Siew C Ng, Rupert W Leong, Peeyush Kumar, Xin Hui Khoo, Govind K Makharia, Jose Sollano, Pises Pisespongsa, Nazri Mustaffa, Rupa Banerjee, Alex Hwong-Ruey Leow, Raja Affendi Raja Ali, Sai Wei Chuah, Shanthi Palaniappan, Choon Jin Ooi, Wai K Leung
Inflammatory bowel disease (IBD) is rapidly emerging in the Asia Pacific region. However, there are many challenges in the diagnosis and management of this condition. The Asian Pacific Association of Gastroenterology (APAGE) Working Group on IBD conducted a round table meeting to identify 10 common mistakes in the management of IBD in Asia. To summarize, many physicians still over rely on a definitive histological diagnosis before starting treatment and do not fully establish disease extent such as perianal and proximal gastrointestinal involvement in Crohn's disease (CD) or extent of involvement in ulcerative colitis (UC)...
May 9, 2024: Journal of Gastroenterology and Hepatology
#2
JOURNAL ARTICLE
Georgios Kokkotis, Eirini Filidou, Gesthimani Tarapatzi, Michail Spathakis, Leonidas Kandilogiannakis, Nikolas Dovrolis, Konstantinos Arvanitidis, Ioannis Drygiannakis, Vassilis Valatas, Stergios Vradelis, Vangelis G Manolopoulos, Vasilis Paspaliaris, George Kolios, Giorgos Bamias
BACKGROUND: Oncostatin-M (OSM) is associated with antitumor necrosis factor (anti-TNF)-α resistance in inflammatory bowel disease (IBD) and fibrosis in inflammatory diseases. We studied the expression of OSM and its receptors (OSMR, gp130) on intestinal subepithelial myofibroblasts (SEMFs) and the effect of OSM stimulation on SEMFs. METHODS: The mRNA and protein expression of OSM, OSMR, gp130, and several fibrotic and chemotactic factors were studied in mucosal biopsies and isolated human intestinal SEMFs of patients with IBD and healthy controls (HCs) and in a model of human intestinal organoids (HIOs)...
May 8, 2024: Inflammatory Bowel Diseases
#3
JOURNAL ARTICLE
Edouard Louis, Michal Litkiewicz, Christian Agboton, Alessandro Armuzzi
BACKGROUND: Several biologics are available for the treatment of moderate to severe Crohn's disease, but data to optimize their use are scarce. Vedolizumab (VDZ) is a gut-selective anti-lymphocyte trafficking monoclonal antibody that was approved in 2014 for the treatment of moderate to severe Crohn's disease. Based on real-world evidence, a model was developed to examine the effect of VDZ's position in the treatment sequence on clinical outcomes. OBJECTIVE: The aim of this study was to develop a model using real-world data to investigate how the positioning of VDZ in a sequence of biologic therapies for CD affects clinical effectiveness outcomes of quality-adjusted life-years (QALYS), patient-reported disease activity, and surgery rates...
May 8, 2024: United European Gastroenterology Journal
#4
JOURNAL ARTICLE
Zhi-Hui Chen, Ying-Ying Tang, Si-Yuan Sheng, Chuan-Gang Lu, Kai-Wu Xu, Guan-Jun Chen, Yan-Feng Wang, Yong Gu, Xin-Ming Song, Hai Hong
BACKGROUND: Crohn's disease (CD) is a chronic inflammatory bowel disease with significant morbidity, affecting millions worldwide. The intricacies of immune responses in CD, especially post-treatment, remain a vital area of exploration. While memory T (Tm)-cell subsets play a pivotal role in adaptive immunity, their specific function in patients with CD after treatment is not well-understood. This study aims to investigate the effect and function of Tm-cell subsets in these patients, addressing a crucial knowledge gap in the context of CD therapeutics...
2024: Translational Gastroenterology and Hepatology
#5
JOURNAL ARTICLE
Iago Rodríguez Lago, Claudia Herrera de Guise, Maia Boscá Watts, Cristina Rodríguez, Eduardo Leo Carnerero, María Calvo Íñiguez, Fiorella Cañete, Silvia Chacón, Camila Cuarán, Ainara Elorza, Elena Guerra Del-Río, Eva Iglesias, Damián Sánchez, Manuel Barreiro de Acosta, Daniel Ginard, José Luis Cabriada
OBJECTIVE: Granulocyte-monocyte apheresis (GMA) has shown to be safe and effective in ulcerative colitis (UC), also in combination with biologics, mainly with anti-TNF. The aim of this study was to evaluate the efficacy and safety of combining GMA after primary non-response (PNR) or loss of response (LOR) to ustekinumab (UST) in patients with UC. PATIENTS AND METHODS: A retrospective study was performed in 12 IBD Units, including all patients with refractory UC or unclassified IBD (IBD-U) who received combined GMA plus UST...
May 4, 2024: Gastroenterología y Hepatología
#6
JOURNAL ARTICLE
Gemma Pujol-Muncunill, Víctor Manuel Navas-López, Oren Ledder, Shlomi Cohen, Marina Lekar, Dan Turner, Kaija-Leena Kolho, Arie Levine, Nicholas M Croft, Jiri Bronsky, Dror S Shouval, Amit Assa, Rachel Harris, Fevronia Kiparissi, Marina Aloi, Nadeem Ahmad Afzal, Christos Tzivinikos, Josefa Barrio, Christoph Norden, Maria Jesús Balboa Vega, Stephan Buderus, Ana Fernández de Valderrama, Lissy de Ridder, Ruth García-Romero, Enrique Medina, César Sánchez, Marta Velasco, Saioa Vicente, David C Wilson, Sandhia Naik, Ondrej Hradsky, Lucia Cococcioni, Javier Martin-de-Carpi
Ustekinumab is an effective therapy for adult Crohn's disease (CD), but data in paediatric CD patients are scarce. The aim of the study was to describe the real-life effectiveness and safety of ustekinumab in paediatric CD. This is a multicentre review of children with Crohn's disease treated with ustekinumab. The aim of our study was to describe the effectiveness and safety of ustekinumab in paediatric real-life practice. This is a study of the Paediatric IBD (inflammatory bowel disease) Porto group of ESPGHAN...
May 3, 2024: European Journal of Pediatrics
#7
REVIEW
Elham Behrangi, Farzan Moodi, Alireza Jafarzadeh, Azadeh Goodarzi
INTRODUCTION: Due to the increasing prevalence of immune-mediated diseases such as psoriasis, lichen planus, rheumatoid arthritis and inflammatory bowel disease, dermatologists have turned to new biologic drugs known as DMARDs (disease-modifying anti-rheumatic drugs) in recent years. AREAS COVERED: In this study, we evaluate the immune-mediated dermatological side effects of DMARDS by reviewing and analyzing previous peer-reviewed research on the effects of TNF-α inhibitors in the treatment of skin diseases, as well as adverse effects of these drugs and some of the main causes of these effects...
May 2024: Skin Research and Technology
#8
JOURNAL ARTICLE
Dwight A Winter, Pauline de Bruyne, Janneke van der Woude, Dimitris Rizopoulos, Lissy de Ridder, Janneke Samsom, Johanna C Escher
OBJECTIVES: Paediatric and adult inflammatory bowel disease (pIBD, aIBD) patients may lose response to anti-TNF treatment within the first year. Adult-extrapolated weight-based dosing is incorrect in children, due to age-related pharmacokinetic differences. We investigated biomarkers for initial and maintenance of response to infliximab (IFX) or adalimumab (ADA), comparing pIBD and aIBD patients. METHODS: In this prospective, observational study, pIBD (n = 24) and aIBD (n = 21) patients were included when initiating anti-TNF...
May 2, 2024: Journal of Pediatric Gastroenterology and Nutrition
#9
JOURNAL ARTICLE
Bahar Saberzadeh-Ardestani, Amir Ali Khosravi, Fariborz Mansour-Ghanaei, Homayoon Vahedi, Nadieh Baniasadi, Mohammadreza Seyyedmajidi, Baran Parhizkar, Ahmad Hormati, Sayed Jalalledin Naghshbandi, Somaieh Matin, Amir Abbas Hassan Zadeh, Tarang Taghvaei, Mohsen Bahrami, Mandana Rafeey, Mitra Ahadi, Hassan Vossoughinia, Hashem Muosavi, Shahsanam Gheibi, Roya-Sadat Hosseini-Hemmatabadi, Abbas Yazdanbod, Saied Matinkhah, Farshad Sheikh Esmaeili, Hafez Fakheri, Seyed Hamid Moosavy, Iradj Maleki, Siavosh Nasseri-Moghaddam, Bardia Khosravi, Fatemeh Farahmand, Mehri Najafi, Hosein Alimadadi, Masoud Malekzadeh, Amir Anushiravani, Amir Kasaeian, Sudabeh Alatab, Anahita Sadeghi, Amir Reza Radmard, Shadi Kolahdoozan, Zeynab Rajabi, Ali Reza Sima
BACKGROUND: Data on the epidemiology of inflammatory bowel disease (IBD) in the Middle East are scarce. We aimed to describe the clinical phenotype, disease course, and medication usage of IBD cases from Iran in the Middle East. METHODS: We conducted a cross-sectional study of registered IBD patients in the Iranian Registry of Crohn's and Colitis (IRCC) from 2017 until 2022. We collected information on demographic characteristics, past medical history, family history, disease extent and location, extra-intestinal manifestations, IBD medications, and activity using the IBD-control-8 questionnaire and the Manitoba IBD index, admissions history, history of colon cancer, and IBD-related surgeries...
April 1, 2024: Archives of Iranian Medicine
#10
JOURNAL ARTICLE
Nermin Salkić, Mirela Bašić Denjagić, Nađa Zubčević, Renata Tamburić, Azra Husić Selimović, Emil Babić, Milenko Bevanda, Aida Saray, Predrag Jovanović, Zoran Tošić, Aleksandar Dobrovoljski, Tatjana Barać
Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), necessitates effective management strategies. This study aims to evaluate the real-world efficacy of vedolizumab, a newer biological therapy, in treating IBD in Bosnia and Herzegovina. A retrospective observational study was conducted across 6 medical centers, involving 139 IBD patients, 76 with UC and 63 with CD. Patients were assessed for clinical remission and other outcomes at the 26-week mark post vedolizumab treatment initiation...
April 28, 2024: Biomol Biomed
#11
JOURNAL ARTICLE
Consuelo Romero-Sánchez, Carlos Ferrer-Santos, Deisy Abril, Eduin Acosta-Hernández, Juliette De Ávila, Alejandro Ramos-Casallas, Javier Escobar, Wilson Bautista-Molano, Diego Jaimes, Adriana Beltrán-Ostos, Juan Manuel Bello-Gualtero, Cristian Flórez-Sarmiento, Viviana Parra-Izquierdo, Omar Javier Calixto
OBJECTIVE: To compare the diversity and composition of the gastrointestinal microbiome of patients with SpA. METHODS: MiSeq sequencing of the V3-V4 region of the 16S ribosomal RNA gene was performed on DNA isolated from stool. Patients with concurrent SpA and IBD were excluded. Differences were assessed for richness and diversity indices by QIIME 2™. Differences between means >0,2% with a p-value<0,05 were assumed significant. Institutional Ethics Committee endorsement...
February 1, 2024: Revista Alergia Mexico: Organo Oficial de la Sociedad Mexicana de Alergia e Inmunología, A.C
#12
JOURNAL ARTICLE
Rogério Serafim Parra, Júlio Maria Fonseca Chebli, Matheus Freitas Cardoso de Azevedo, Liliana Andrade Chebli, Gilmara Pandolfo Zabot, Ornella Sari Cassol, Renata de Sá Brito Fróes, Genoile Oliveira Santana, Márcio Lubini, Daniela Oliveira Magro, Marcello Imbrizi, Antonio Carlos da Silva Moraes, Fabio Vieira Teixeira, Antonio José Tiburcio Alves Junior, Newton Luiz Tricarico Gasparetti Junior, Sandro da Costa Ferreira, Natália Sousa Freitas Queiroz, Paulo Gustavo Kotze, Omar Féres
BACKGROUND: Real-world data on the effectiveness and safety of ustekinumab (UST) in ulcerative colitis (UC) are lacking in Latin America. In this study, we aimed to describe the effectiveness and safety of UST in a real-world multicenter cohort of Brazilian patients with UC. METHODS: We conducted a multicenter retrospective observational cohort study, including patients with moderate-to-severe UC (total Mayo score 6-12, with an endoscopic subscore of 2 or 3) who received UST...
April 2024: Crohn's & colitis 360
#13
JOURNAL ARTICLE
Mohammad Shehab, Fatema Alrashed, Munerah Alyaseen, Zainab Safar, Tunrayo Adekunle, Ahmad Alfadhli, Talat Bessissow
INTRODUCTION: Hepatitis B virus (HBV) infection has been associated with chronic hepatitis and cirrhosis. Patients with inflammatory bowel disease (IBD) may be at a higher risk of HBV infection reactivation, especially those on biologic therapies. This study intends to compare the effectiveness of the HBV vaccine in patients with ulcerative colitis (UC) on infliximab (IFX) compared to those on 5-aminosalicylic acid (5-ASA). METHODS: Patients with UC aged >18 years old were prospectively enrolled in the study...
March 27, 2024: Vaccines
#14
REVIEW
Katarzyna Stasik, Rafał Filip
Patients with inflammatory bowel disease may be at higher risk of developing lymphomas and other cancers of the gastrointestinal tract. In addition, there may be a link between the use of thiopurines or anti-tumor necrosis factor drugs (anti-TNF) and these pathologies. The treatment of patients with Crohn's disease who have previously been diagnosed with lymphoma is a challenge for gastroenterologists. In this report, we examine important clinical issues related to the treatment of patients with inflammatory bowel disease with active lymphoma, as well as of patients with hematological cancer history...
April 11, 2024: International Journal of Molecular Sciences
#15
REVIEW
Mohmmed Tauseef Sharip, Nilanga Nishad, Lushen Pillay, Nilkantsingh Goordoyel, Samuel Goerge, Sreedhar Subramanian
Background: Anti-tumour necrosis factor (TNF) agents are effective in Crohn's disease (CD), but some patients lose responsiveness and require alternative biologic therapy. Until recently, ustekinumab and vedolizumab were the only other biological agents approved for use in CD. There are no randomised trials which compare the efficacy of these two agents in patients with anti-TNF refractory disease, but several retrospective cohort studies have compared their effectiveness in this setting. Aim: To review the effectiveness of ustekinumab and vedolizumab in anti-TNF refractory patients with CD...
April 10, 2024: Journal of Clinical Medicine
#16
JOURNAL ARTICLE
Amelie Köhler, Anna-Lena Geiselhöringer, Daphne Kolland, Luisa Kreft, Nina Wichmann, Miriam Hils, Maria Pasztoi, Elena Zurkowski, Johannes Vogt, Tanja Kübelbeck, Tilo Biedermann, Ingo Schmitz, Wiebke Hansen, Daniela Kramer, Matthias M Gaida, Carsten B Schmidt-Weber, Nadine Hoevelmeyer, Caspar Ohnmacht
Peripherally induced regulatory T cells (pTregs) expressing the retinoic acid receptor-related orphan-receptor gamma t (RORγt) are indispensable for intestinal immune homeostasis. NF-κB family members regulate the differentiation of thymic Tregs and promote their survival in the periphery. However, the Treg-intrinsic molecular mechanisms controling the size of the pTregs in the intestine and associated lymphoid organs remain unclear. Here, we provide direct evidence that Bcl3 limits the development of pTregs in a T cell-intrinsic manner...
April 23, 2024: Mucosal Immunology
#17
REVIEW
Antonio Meštrović, Marko Kumric, Josko Bozic
The timely introduction and adjustment of the appropriate drug in accordance with previously well-defined treatment goals is the foundation of the approach in the treatment of inflammatory bowel disease (IBD). The therapeutic approach is still evolving in terms of the mechanism of action but also in terms of the possibility of maintaining remission. In patients with achieved long-term remission, the question of de-escalation or discontinuation of therapy arises, considering the possible side effects and economic burden of long-term therapy...
April 6, 2024: World Journal of Clinical Cases
#18
JOURNAL ARTICLE
Kentaro Kojima, Kenji Watanabe, Mikio Kawai, Soichi Yagi, Koji Kaku, Maiko Ikenouchi, Toshiyuki Sato, Koji Kamikozuru, Yoko Yokoyama, Tetsuya Takagawa, Masahito Shimizu, Shinichiro Shinzaki
BACKGROUND: Real-world data on tofacitinib (TOF) covering a period of more than 1 year for a sufficient number of Asian patients with ulcerative colitis (UC) are scarce. AIM: To investigate the long-term efficacy and safety of TOF treatment for UC, including clinical issues. METHODS: We performed a retrospective single-center observational analysis of 111 UC patients administered TOF at Hyogo Medical University as a tertiary inflammatory bowel disease center...
April 7, 2024: World Journal of Gastroenterology: WJG
#19
JOURNAL ARTICLE
Andres Yarur, Gerassimos J Mantzaris, Song Wang, Shashi Adsul, Pravin Kamble, Erin Cook, Gautam Sajeev, Annie Guerin, Brian Bressler
INTRODUCTION: This analysis evaluated the relative performance of vedolizumab and anti-tumor necrosis factor alpha (anti-TNFα) agents in subpopulations of biologic therapy-naive patients with Crohn's disease (CD) and assessed whether patients in whom vedolizumab would have a larger treatment effect vs anti-TNFα agents could be identified. METHODS: Data were from EVOLVE, a real-world, multicountry, retrospective cohort study of patients with inflammatory bowel disease who initiated first-line biologic treatment with vedolizumab (n = 195) or anti-TNFα agents (n = 245)...
April 24, 2024: Advances in Therapy
#20
JOURNAL ARTICLE
Meng Sun, Jingyi Ju, Hongzhen Xu, Mengqi Luo, Zhaoyang Li, Yufang Wang
Aims: The formation of anti-drug antibodies (ADAs) during anti-tumor necrosis factor (anti-TNF) therapy is reported to lead to reducing serum drug levels, which may bring about a loss of response to treatment. Previous research has suggested an association between specific antibiotic classes and ADA formation during anti-TNF therapy. However, there are few studies specifically examining this association in Chinese inflammatory bowel disease (IBD) patients. Therefore, our study aimed to evaluate the possible effect of antibiotic use on ADA formation to anti-TNF therapy in Chinese patients with IBD...
2024: Frontiers in Pharmacology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
